The NGI Pre-Separator: Designed for Formulations with Large Carrier Particles

BACKGROUND: Compendial methods recommend including a pre-separator (PS) before the multi-stage impactor when testing dry powder inhalers (DPIs) for emitted aerosol aerodynamic particle size distribution (APSD). For data analysis, they are either silent or treat the PS as a "non-sizing" component. The overall message is "use the PS but ignore what it collects." The Next Generation Impactor (NGI) PS reinforces this mindset because it was specifically designed for testing carrier-particle-based DPIs wherein any API in the PS results from a failure to detach from the large carrier particles. However, users with carrier-free DPI formulations might wonder what to do if drug is found in the PS and if it is technically justified to omit this component, thereby increasing laboratory throughput by relying on the NGI alone to provide accurate APSD metrics. METHODS: Particle capture efficiency curves for the NGI PS were constructed from the published calibration data at flow rates of 15, 30, 60, and 100 L/min. These curves and those published for NGI stages 1-7 enabled calculation of how model input aerosols disperse throughout an NGI with or without a PS. APSD metrics were subsequently estimated from these calculated API mass fractions and then compared with and without the PS. RESULTS: The presence of the PS yielded APSD metrics for the model aerosols that were almost indistinguishable from those obtained without the PS, accounting for the API mass recovered from the PS as if it had collected on an impactor stage. CONCLUSIONS: The PS is necessary when and only when the formulation contains large carrier particles. Consequently, for carrier-free formulations, method validation with no PS is likely to succeed. If for any reason it is retained in the test method of a carrier-free formulation, the PS should be treated like an impactor stage for APSD data analysis purposes.

Authors

Publication Details

Journal
Journal of Aerosol Medicine and Pulmonary Drug Delivery
Published
2026-11-13
DOI
https://doi.org/10.1177/19412711261506512
Primary Topic
Inhalation and Respiratory Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The NGI Pre-Separator: Designed for Formulations with Large Carrier Particles

Jolyon Paul Mitchell, Daryl L. Roberts
Journal of Aerosol Medicine and Pulmonary Drug Delivery
Inhalation and Respiratory Drug Delivery
article

The NGI Pre-Separator: Designed for Formulations with Large Carrier Particles

Jolyon Paul Mitchell, Daryl L. Roberts
article en

Abstract

BACKGROUND: Compendial methods recommend including a pre-separator (PS) before the multi-stage impactor when testing dry powder inhalers (DPIs) for emitted aerosol aerodynamic particle size distribution (APSD). For data analysis, they are either silent or treat the PS as a "non-sizing" component. The overall message is "use the PS but ignore what it collects." The Next Generation Impactor (NGI) PS reinforces this mindset because it was specifically designed for testing carrier-particle-based DPIs wherein any API in the PS results from a failure to detach from the large carrier particles. However, users with carrier-free DPI formulations might wonder what to do if drug is found in the PS and if it is technically justified to omit this component, thereby increasing laboratory throughput by relying on the NGI alone to provide accurate APSD metrics. METHODS: Particle capture efficiency curves for the NGI PS were constructed from the published calibration data at flow rates of 15, 30, 60, and 100 L/min. These curves and those published for NGI stages 1-7 enabled calculation of how model input aerosols disperse throughout an NGI with or without a PS. APSD metrics were subsequently estimated from these calculated API mass fractions and then compared with and without the PS. RESULTS: The presence of the PS yielded APSD metrics for the model aerosols that were almost indistinguishable from those obtained without the PS, accounting for the API mass recovered from the PS as if it had collected on an impactor stage. CONCLUSIONS: The PS is necessary when and only when the formulation contains large carrier particles. Consequently, for carrier-free formulations, method validation with no PS is likely to succeed. If for any reason it is retained in the test method of a carrier-free formulation, the PS should be treated like an impactor stage for APSD data analysis purposes.

Journal of Aerosol Medicine and Pulmonary Drug Delivery
Good health and well-being
Inhalation and Respiratory Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon